HK1200447A1 - 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors - Google Patents

1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors Download PDF

Info

Publication number
HK1200447A1
HK1200447A1 HK15100794.1A HK15100794A HK1200447A1 HK 1200447 A1 HK1200447 A1 HK 1200447A1 HK 15100794 A HK15100794 A HK 15100794A HK 1200447 A1 HK1200447 A1 HK 1200447A1
Authority
HK
Hong Kong
Prior art keywords
pyridin
pyrrolo
pyrazole
carboxylic acid
benzyl
Prior art date
Application number
HK15100794.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬．斯托克斯
克里斯多佛．約翰．格雷厄姆
克里斯多佛．约翰．格雷厄姆
斯圖亞特．克里斯多佛．雷
斯图亚特．克里斯多佛．雷
艾瑪．杰妮．斯蒂芬尼亞克
艾玛．杰妮．斯蒂芬尼亚克
Original Assignee
沃纳利斯(R&D)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 沃纳利斯(R&D)有限公司 filed Critical 沃纳利斯(R&D)有限公司
Publication of HK1200447A1 publication Critical patent/HK1200447A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15100794.1A 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors HK1200447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
GB1201566.5 2012-01-30
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1200447A1 true HK1200447A1 (en) 2015-08-07

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100794.1A HK1200447A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Country Status (21)

Country Link
US (3) US10000481B2 (instruction)
EP (1) EP2809670B1 (instruction)
JP (1) JP6199316B2 (instruction)
CN (4) CN107011341A (instruction)
AU (1) AU2013213954B2 (instruction)
BR (1) BR112014018795B1 (instruction)
CA (1) CA2862940C (instruction)
DK (1) DK2809670T3 (instruction)
EA (1) EA026657B1 (instruction)
ES (1) ES2637340T3 (instruction)
GB (1) GB201201566D0 (instruction)
HK (1) HK1200447A1 (instruction)
HU (1) HUE035332T2 (instruction)
IL (1) IL233595B (instruction)
IN (1) IN2014DN06104A (instruction)
MX (1) MX352927B (instruction)
NZ (1) NZ627361A (instruction)
PL (1) PL2809670T3 (instruction)
PT (1) PT2809670T (instruction)
WO (1) WO2013114113A1 (instruction)
ZA (1) ZA201405070B (instruction)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
MY168958A (en) * 2012-04-23 2019-01-28 Genentech Inc Intermediates and processes for preparing compounds
US10329288B2 (en) 2013-08-22 2019-06-25 Genentech, Inc. Process for preparing a compound
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
WO2017146116A1 (ja) 2016-02-23 2017-08-31 大鵬薬品工業株式会社 新規縮合ピリミジン化合物又はその塩
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
KR20220042159A (ko) 2019-08-01 2022-04-04 인테그랄 바이오사이언스 피브이티. 엘티디. 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
WO2022015979A1 (en) * 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN116157394A (zh) 2020-07-15 2023-05-23 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
US12152018B2 (en) 2021-01-08 2024-11-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity
JP2025503675A (ja) * 2022-01-12 2025-02-04 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
US8841304B2 (en) * 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
MX2010007525A (es) * 2008-01-22 2010-08-18 Vernalis R&D Ltd Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control.
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
MX2010013606A (es) * 2008-06-11 2010-12-21 Genentech Inc Diazacarbazoles y metodos de uso.
JP5718332B2 (ja) * 2009-08-06 2015-05-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規な二環式尿素化合物
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Also Published As

Publication number Publication date
CN106866658A (zh) 2017-06-20
CN104203948A (zh) 2014-12-10
GB201201566D0 (en) 2012-03-14
EP2809670B1 (en) 2017-05-17
EA201491376A1 (ru) 2015-01-30
US10889582B2 (en) 2021-01-12
EP2809670A1 (en) 2014-12-10
US10000481B2 (en) 2018-06-19
JP6199316B2 (ja) 2017-09-20
US20210206762A1 (en) 2021-07-08
CN107011341A (zh) 2017-08-04
IL233595A0 (en) 2014-08-31
WO2013114113A1 (en) 2013-08-08
PL2809670T3 (pl) 2017-10-31
DK2809670T3 (en) 2017-08-28
MX2014009112A (es) 2014-11-10
PT2809670T (pt) 2017-08-23
BR112014018795A2 (pt) 2017-07-04
IL233595B (en) 2018-05-31
BR112014018795B1 (pt) 2020-09-29
US20180362526A1 (en) 2018-12-20
CA2862940C (en) 2021-09-14
IN2014DN06104A (instruction) 2015-08-14
EA026657B1 (ru) 2017-05-31
CA2862940A1 (en) 2013-08-08
AU2013213954B2 (en) 2016-02-25
NZ627361A (en) 2016-07-29
AU2013213954A1 (en) 2014-08-07
MX352927B (es) 2017-12-14
CN111484493A (zh) 2020-08-04
HUE035332T2 (en) 2018-05-02
JP2015505555A (ja) 2015-02-23
CN106866658B (zh) 2021-04-27
US20150011533A1 (en) 2015-01-08
ZA201405070B (en) 2016-03-30
ES2637340T3 (es) 2017-10-11

Similar Documents

Publication Publication Date Title
CN106866658B (zh) 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
JP7317878B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
EP3774789B1 (en) Brm targeting compounds and associated methods of use
CN109970743B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
JP2022500368A (ja) 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法
CN110088096A (zh) 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
CN112513024A (zh) Tlr7/8拮抗剂及其用途
CN108473478A (zh) TBK/IKKε抑制剂化合物及其用途
US20240158370A1 (en) CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (zh) 1h-吡咯并[2，3-b]吡啶衍生物及他们作为激酶抑制剂的用途
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK40010369A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40010369B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
HK1233621A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors